Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
COVID-19
RBD
SARS-CoV-2
escape
neutralizing antibodies
spike
variants
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
12 Mar 2021
12 Mar 2021
Historique:
pubmed:
24
2
2021
medline:
24
2
2021
entrez:
23
2
2021
Statut:
epublish
Résumé
Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2. However, ongoing surveillance has revealed the emergence of variants harboring mutations in spike, the main target of neutralizing antibodies. To understand the impact of these variants, we evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2. Five of the 10 pseudoviruses, harboring receptor-binding domain mutations, including K417N/T, E484K, and N501Y, were highly resistant to neutralization. Crossneutralization of B.1.351 variants was comparable to SARS-CoV and bat-derived WIV1-CoV, suggesting that a relatively small number of mutations can mediate potent escape from vaccine responses. While the clinical impact of neutralization resistance remains uncertain, these results highlight the potential for variants to escape from neutralizing humoral immunity and emphasize the need to develop broadly protective interventions against the evolving pandemic.
Identifiants
pubmed: 33619506
doi: 10.1101/2021.02.14.21251704
pmc: PMC7899476
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007245
Pays : United States
Commentaires et corrections
Type : UpdateIn
Type : UpdateIn
Déclaration de conflit d'intérêts
DECLARATIONS OF INTEREST The authors declare no competing interests.
Références
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Cell Mol Immunol. 2021 Feb;18(2):318-327
pubmed: 33408342
Cell. 2021 Jan 21;184(2):476-488.e11
pubmed: 33412089
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Cell Res. 2021 Jun;31(6):720-722
pubmed: 33893398
Cell Rep. 2021 Mar 23;34(12):108890
pubmed: 33713594
Cell. 2020 Oct 29;183(3):739-751.e8
pubmed: 32991842
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
J Virol. 2004 Oct;78(19):10628-35
pubmed: 15367630
Nature. 2021 Apr;592(7852):116-121
pubmed: 33106671
Science. 2021 Jan 8;371(6525):172-177
pubmed: 33172935
Science. 2020 Nov 13;370(6518):856-860
pubmed: 33082293
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
Nat Commun. 2020 May 4;11(1):2251
pubmed: 32366817
Science. 2021 Mar 12;371(6534):1152-1153
pubmed: 33514629
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3
pubmed: 33705729
Science. 2020 Aug 21;369(6506):1014-1018
pubmed: 32540904
Viruses. 2020 Dec 09;12(12):
pubmed: 33316947
Cell Host Microbe. 2021 Jan 13;29(1):44-57.e9
pubmed: 33259788
Cell Mol Immunol. 2021 Apr;18(4):1061-1063
pubmed: 33633321
Vaccines (Basel). 2020 Dec 28;9(1):
pubmed: 33379160
Nat Med. 2021 Mar;27(3):440-446
pubmed: 33531709
J Biomol Screen. 2013 Apr;18(4):453-61
pubmed: 23112084
Viruses. 2020 May 06;12(5):
pubmed: 32384820
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Science. 2020 Dec 18;370(6523):1464-1468
pubmed: 33184236
Biosaf Health. 2020 Dec;2(4):226-231
pubmed: 32864605
MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):95-99
pubmed: 33476315